Agilon Health | AGL | Long at $2.24

l’altro ieri

Agilon Health AGL

Pros:

• Revenue consistently grew from 2019 ($794 million) to 2023 ($4.3 billion) and through three quarters of 2024 ($5.6 billion). Expected to reach $8.7 billion by 2027.
  
• Current debt-to-equity ratio 0.06 (very low)
  
• Sufficient cash reserves to fund operations and strategic initiatives
  
• Strong membership growth (525,000 as of Q3 2024, a 37% year-over-year increase)
  
• Recent insider buying ($2 - $3) and awarding of options
  

Cons:

• Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
  
• No dividend
  

Targets (into 2027):

1. $2.72
   
2. $4.00
   
3. $5.00
   
4. $7.00
   
5. $11.50
   
6. $16.00